Vir Biotechnology, Inc.
VIR
$4.38
$0.020.46%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -60.52% | -94.62% | -26.29% | -9.81% | -19.02% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -60.52% | -94.62% | -26.29% | -9.81% | -19.02% |
| Cost of Revenue | -7.27% | 19.36% | -16.53% | 34.58% | -37.44% |
| Gross Profit | 5.67% | -171.79% | 14.70% | -35.40% | 37.87% |
| SG&A Expenses | -26.37% | -34.08% | -35.22% | -37.11% | -33.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.54% | 4.97% | -21.75% | 18.80% | -36.60% |
| Operating Income | 10.40% | -76.51% | 21.16% | -19.21% | 36.92% |
| Income Before Tax | 20.80% | -86.08% | 13.32% | -28.16% | 29.21% |
| Income Tax Expenses | 111.24% | -94.20% | 98.20% | 105.51% | 46.91% |
| Earnings from Continuing Operations | 19.82% | -85.31% | 9.82% | -30.78% | 28.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.82% | -85.31% | 9.82% | -30.78% | 28.95% |
| EBIT | 10.40% | -76.51% | 21.16% | -19.21% | 36.92% |
| EBITDA | 9.70% | -83.42% | 20.65% | -20.65% | 37.54% |
| EPS Basic | 21.11% | -82.36% | 11.27% | -28.52% | 30.08% |
| Normalized Basic EPS | 7.19% | -116.23% | 21.09% | -23.62% | 40.04% |
| EPS Diluted | 21.11% | -82.36% | 11.72% | -28.52% | 30.08% |
| Normalized Diluted EPS | 7.19% | -116.23% | 21.09% | -23.62% | 40.04% |
| Average Basic Shares Outstanding | 1.63% | 1.62% | 1.63% | 1.76% | 1.61% |
| Average Diluted Shares Outstanding | 1.63% | 1.62% | 1.63% | 1.76% | 1.61% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |